These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

168 related items for PubMed ID: 6756854

  • 1. [Buflomedil in arterial occlusive disease. Results of a controlled study].
    Trübestein G, Balzer K, Bisler H, Klüken N, Mahfoud Y, Müller-Wiefel H, Unkel B, Ziegler W.
    Dtsch Med Wochenschr; 1982 Dec 24; 107(51-52):1957-61. PubMed ID: 6756854
    [No Abstract] [Full Text] [Related]

  • 2. Buflomedil in arterial occlusive disease: results of a controlled multicenter study.
    Trübestein G, Balzer K, Bisler H, Klüken N, Muller-Wiefel H, Unkel B, Mahfoud Y, Ziegler W.
    Angiology; 1984 Aug 24; 35(8):500-5. PubMed ID: 6383127
    [Abstract] [Full Text] [Related]

  • 3. [Effectiveness of buflomedil in arterial occlusive disease. Modification of transcutaneous oxygen pressure in a placebo-controlled double-blind study].
    Sunder-Plassmann L, Gandolfo AM, Utz C.
    MMW Munch Med Wochenschr; 1984 Mar 02; 126(9):247-8. PubMed ID: 6425678
    [No Abstract] [Full Text] [Related]

  • 4. [Action and tolerability of delayed-action buflomedil in obliterating arteriopathies of the lower limbs. A multicenter study].
    Andreozzi GM, Lepore R.
    Clin Ter; 1990 Nov 30; 135(4):273-81. PubMed ID: 2150026
    [Abstract] [Full Text] [Related]

  • 5. A review of long-term safety data with buflomedil.
    Bachand RT, Dubourg AY.
    J Int Med Res; 1990 Nov 30; 18(3):245-52. PubMed ID: 2193838
    [Abstract] [Full Text] [Related]

  • 6. [Clinical experience and instrumental evaluation of buflomedil hydrochloride in the therapy of chronic obliterative arteriopathies of the legs].
    Lucisano V, Margheriti R, Matone P, Morrieri C, Rugolo A, Corsi V.
    Clin Ter; 1986 Jun 30; 117(6):499-509. PubMed ID: 3527536
    [No Abstract] [Full Text] [Related]

  • 7. Positive effect of oral buflomedil on exercise-induced haemorheological damage and on claudication distance in peripheral obliterative arterial disease patients.
    Forconi S, Pieragalli D, Acciavatti A, Del Bigo C, Galigani C, Ralli L, Guerrini M, Di Perri T.
    J Int Med Res; 1984 Jun 30; 12(3):188-92. PubMed ID: 6734922
    [No Abstract] [Full Text] [Related]

  • 8. [Double-blind study of naftidrofuryl-hydrogen oxalate in peripheral arterial occlusive disease].
    Pohle W, Hirche H, Barmeyer J, Schümichen C, Hoffmann G.
    Med Welt; 1979 Feb 16; 30(7):269-72. PubMed ID: 372733
    [No Abstract] [Full Text] [Related]

  • 9. [Buflomedil chlorhydrate in peripheral vasculopathies].
    Dall'Antonia F, Perbellini A, Adami CA, Dal Cortivo G, Bucci S.
    Clin Ter; 1986 Dec 15; 119(5):379-85. PubMed ID: 2951055
    [No Abstract] [Full Text] [Related]

  • 10. A placebo-controlled study of the effects of intravenous Buflomedil on foot skin microcirculation in patients with severe intermittent claudication.
    Van den Brande P, Maurel A.
    Angiology; 1998 Feb 15; 49(2):105-14. PubMed ID: 9482510
    [Abstract] [Full Text] [Related]

  • 11. [New data on vasoactive drug. Patients with peripheral arterial occlusive disease walk twice as long].
    MMW Fortschr Med; 2002 May 23; 144(21):54. PubMed ID: 12134429
    [No Abstract] [Full Text] [Related]

  • 12. [Comparison of 2 effective doses of Fludilat in peripheral vascular disorders in a double-blind trial].
    König FK.
    Med Welt; 1973 Sep 28; 24(39):1490-2. PubMed ID: 4588974
    [No Abstract] [Full Text] [Related]

  • 13. [Bencyclane in stage II arterial occlusive disease. Results of a controlled study].
    Trübestein G, Trübestein R, Ludwig M.
    Fortschr Med; 1989 Dec 20; 107(36):781-4. PubMed ID: 2695437
    [Abstract] [Full Text] [Related]

  • 14. [Naftidrofuryl in arterial occlusive disease. Controlled multicenter double-blind study with oral administration].
    Maass U, Amberger HG, Böhme H, Diehm C, Dimroth H, Heidrich H, Heinrich F, Hirche H, Mörl H, Müller-Bühl U.
    Dtsch Med Wochenschr; 1984 May 11; 109(19):745-50. PubMed ID: 6373217
    [Abstract] [Full Text] [Related]

  • 15. Oral buflomedil in the prevention of cardiovascular events in patients with peripheral arterial obstructive disease: a randomized, placebo-controlled, 4-year study.
    Limbs International Medicinal Buflomedil (LIMB) Study Group, Leizorovicz A, Becker F.
    Circulation; 2008 Feb 12; 117(6):816-22. PubMed ID: 18212283
    [Abstract] [Full Text] [Related]

  • 16. Buflomedil for intermittent claudication.
    De Backer TL, Vander Stichele RH, Bogaert MG.
    Cochrane Database Syst Rev; 2001 Feb 12; (1):CD000988. PubMed ID: 11279700
    [Abstract] [Full Text] [Related]

  • 17. Clinical and hemorheological effects of buflomedil in diabetic subjects with intermittent claudication.
    Diamantopoulos EJ, Grigoriadou M, Ifanti G, Raptis SA.
    Int Angiol; 2001 Dec 12; 20(4):337-44. PubMed ID: 11782701
    [Abstract] [Full Text] [Related]

  • 18. Pentoxifylline (Trental)--a new drug for the treatment of peripheral chronic occlusive arterial disease.
    Chopra HK, Chopra KL, Aggarwal KK, Parashar SK.
    J Med; 1988 Dec 12; 19(2):89-107. PubMed ID: 3049876
    [Abstract] [Full Text] [Related]

  • 19. [Effect of buflomedil perfusion on peripheral tissue oxygenation during transluminal angioplasty in patients with advanced arteriopathy of the lower limbs].
    Joffre F, Meites G, Rousseau H, Staffin C, Allaert FA, Pelat P.
    Ann Radiol (Paris); 1994 Dec 12; 37(3):239-44. PubMed ID: 8092756
    [Abstract] [Full Text] [Related]

  • 20. [Buflomedil in the treatment of chronic peripheral arterial diseases. Case contribution].
    Visconti W, Grillo N.
    Minerva Med; 1985 May 12; 76(19-20):945-53. PubMed ID: 3158842
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.